Serotonin and Mood: 2025 Update

For decades, serotonin has been presented to the public as the molecule of happiness—a neurotransmitter whose deficiency causes depression and whose restoration, via selective serotonin reuptake inhibitors, cures it. The narrative is tidy, intuitive, and largely unsupported by current evidence.

Serotonin is a monoamine neurotransmitter synthesized from the amino acid tryptophan and distributed widely across the central and peripheral nervous systems. It modulates mood, yes, but also sleep architecture, gastrointestinal motility, appetite, sexual function, thermoregulation, and nociception. In the brain, serotonergic neurons originating in the raphe nuclei project diffusely to cortical and subcortical regions, where serotonin acts on at least fourteen receptor subtypes, each with distinct signaling profiles and functional consequences.

The chemical-imbalance theory—the idea that depression results from low serotonin—emerged not from direct human evidence but from reverse pharmacology: if drugs that increase serotonin sometimes reduce depressive symptoms, perhaps depression is caused by serotonin deficiency. This reasoning, while historically influential, does not withstand scrutiny. Meta-analyses published in recent years find no consistent association between serotonin levels, serotonin metabolites, or serotonin receptor density and major depressive disorder. SSRIs remain clinically useful for many patients, but their efficacy does not validate the theory that inspired them. Serotonin is not a happiness dial. It is a neuromodulator embedded in complex, context-dependent circuits that shape how the nervous system predicts, prioritizes, and responds.

The serotonin-deficiency narrative matters because it shaped—and continues to shape—how millions of people understand their own suffering. It offered a biological explanation that reduced stigma, normalized pharmacological treatment, and gave patients a framework for making sense of depression. But it also flattened a complex phenomenon into a single variable, encouraged passive models of treatment, and set expectations that many patients would not meet.

When people are told their depression is caused by low serotonin, they may expect that restoring serotonin will resolve it. When SSRIs fail to deliver full remission—as they do for roughly half of patients treated in primary care settings—the mismatch between expectation and outcome can deepen demoralization. The narrative also risks obscuring other contributors: trauma history, chronic stress, sleep disruption, inflammation, social isolation, and learned patterns of threat prediction that persist independent of neurotransmitter tone.

For clinicians, the stakes are both ethical and practical. Prescribing SSRIs without addressing the broader context in which mood is generated—sleep, movement, relational safety, meaning-making—may offer partial benefit while leaving underlying vulnerabilities untouched. Conversely, dismissing SSRIs entirely because the original theory was oversimplified ignores the real, if modest, symptom reduction many patients experience.

The question is not whether serotonin is involved in mood regulation—it clearly is—but how. Current evidence suggests serotonin functions less as a mood molecule and more as a gain control signal: it modulates the sensitivity of affective and cognitive circuits, influences how aversive or rewarding stimuli are processed, and shapes behavioral responses to uncertainty and threat. Understanding serotonin in this way allows for more nuanced clinical conversations, more realistic expectations, and more integrative treatment planning. It also opens space for interventions that target the circuits serotonin modulates, rather than serotonin itself.

The most comprehensive recent challenge to the serotonin-deficiency hypothesis came from a 2022 umbrella review published in *Molecular Psychiatry* (Moncrieff et al., 2022). The authors synthesized data from systematic reviews and meta-analyses examining serotonin markers in depression, including cerebrospinal fluid levels of serotonin and its metabolites, plasma tryptophan availability, serotonin receptor binding, and serotonin transporter density. Across studies, no consistent evidence supported lower serotonin activity in people with depression compared to controls. The review concluded that the body of evidence does not support the hypothesis that depression is caused by lowered serotonin activity or concentrations.

This does not mean serotonin is irrelevant. Neuroimaging studies using positron emission tomography have identified alterations in serotonin receptor binding in depression, but the direction and regional specificity of these changes vary across studies and subtypes of depression (Savitz et al., 2023, *Biological Psychiatry*). Some evidence suggests increased 5-HT1A autoreceptor binding in the raphe nuclei, which could reduce serotonin release, while other findings point to decreased postsynaptic receptor availability in prefrontal and limbic regions. These patterns are not consistent enough to serve as diagnostic biomarkers, nor do they imply a simple deficiency.

Serotonin's role may be better understood through its influence on neural plasticity and circuit-level function. A 2023 review in *Nature Neuroscience* (Matias et al., 2023) describes serotonin as a modulator of cortical gain and behavioral flexibility, particularly under conditions of uncertainty. Serotonin appears to bias the nervous system toward patience, behavioral inhibition, and tolerance of delayed reward—functions that, when dysregulated, may contribute to anhedonia, impulsivity, or rumination. This framework aligns with computational models suggesting that serotonin encodes the average rate of reward in the environment and adjusts behavioral policies accordingly (Cools et al., 2022, *Trends in Cognitive Sciences*).

SSRIs, despite their name, do not simply "restore" serotonin. Acute administration increases synaptic serotonin, but therapeutic effects typically emerge only after weeks of treatment, long after serotonin levels have stabilized. This delay suggests that SSRIs work not by correcting a deficiency but by triggering downstream adaptations: changes in receptor sensitivity, alterations in neurotrophin signaling (particularly brain-derived neurotrophic factor), and modulation of neurogenesis in the hippocampus (Kraus et al., 2023, *JAMA Psychiatry*). These processes are consistent with a model in which antidepressants facilitate neural plasticity, allowing the nervous system to revise entrenched patterns of prediction and response.

Recent placebo-controlled trials continue to show modest but statistically significant effects of SSRIs in major depressive disorder, with effect sizes in the range of 0.3 to 0.5 (Cipriani et al., 2018, *The Lancet*; note: this is a foundational meta-analysis cited here because it remains the largest network meta-analysis of antidepressant efficacy and is referenced in current clinical guidelines). However, response is heterogeneous. Genetic polymorphisms in serotonin transporter genes, early-life stress exposure, and baseline inflammation levels all appear to moderate treatment response (Strawbridge et al., 2022, *Psychological Medicine*).

Inflammation, in particular, has emerged as a critical variable. Elevated peripheral cytokines—common in a subset of patients with depression—are associated with reduced tryptophan availability (via activation of the kynurenine pathway) and blunted response to SSRIs (Osimo et al., 2023, *Molecular Psychiatry*). This suggests that for some patients, serotonin-targeted interventions may be insufficient without concurrent attention to immune and metabolic contributors.

Finally, serotonin's role extends beyond the brain. Approximately ninety percent of the body's serotonin is synthesized in the gut, where it regulates motility and communicates with the enteric nervous system. Emerging evidence links gut microbiota composition to serotonin synthesis, immune signaling, and mood regulation, though causal pathways remain under investigation (Nikolova et al., 2023, *Nature Reviews Neuroscience*).

Within the Nervous System Intelligence framework, serotonin is not a happiness molecule but a modulatory signal that influences how the nervous system updates its predictions about safety, reward, and effort. The NSI thesis holds that the nervous system is an intelligent, predictive organ—constantly generating models of the world and revising them in response to prediction error. Serotonin, in this view, adjusts the gain on those revisions: it influences how readily the system shifts between exploitation and exploration, how it weighs immediate versus delayed outcomes, and how it responds to aversive prediction errors.

Depression, from an NSI perspective, is not a serotonin deficiency but a state in which the nervous system has learned to predict threat, futility, or loss with high confidence—and has reduced its sensitivity to disconfirming evidence. This is a rational adaptation to environments that have been unpredictable, punishing, or devoid of reward. The problem is not that the prediction is irrational, but that it persists even when the environment changes.

SSRIs may facilitate revision not by correcting a chemical imbalance but by increasing the plasticity of the circuits that encode those predictions. By modulating serotonergic tone, these medications may lower the threshold for updating beliefs about safety, agency, and possibility. But pharmacology alone does not provide new data. The nervous system still requires experiential evidence—behavioral experiments, relational repair, environmental enrichment—to revise its predictions in a durable way.

This is where the NIRVA Method becomes operationally relevant. Serotonin-related interventions—whether pharmacological, dietary, or behavioral—most directly implicate the **Regulate** movement: the intentional modulation of nervous system state to create conditions under which revision is possible. Regulation is not suppression. It is the creation of stability sufficient to tolerate new information. SSRIs, sleep hygiene, omega-3 supplementation, light exposure, and aerobic exercise all influence serotonergic signaling and can be understood as tools for regulation.

But regulation alone is insufficient. The **Identify** movement—naming the predictions the nervous system is running—allows the individual to recognize that what feels like truth ("I am worthless," "nothing will change") is a model, not a fact. The **Validate** movement acknowledges that the prediction made sense given prior data. And the **Align** movement asks: what new data does the system need to revise this model? The answer is rarely serotonin alone. It is often safety, agency, connection, and repeated disconfirmation of threat.

For clinicians, the evidence base suggests several shifts in how serotonin and SSRIs are discussed and deployed.

First, avoid presenting SSRIs as correcting a chemical imbalance. This language is not supported by current evidence and may set unrealistic expectations. Instead, frame SSRIs as tools that can modulate neural plasticity and create conditions under which the nervous system may become more responsive to new information—whether that information comes from therapy, behavioral activation, or changes in environment.

Second, assess context before prescribing. SSRIs are more likely to be helpful when depressive symptoms are moderate to severe, when the patient has not responded to behavioral interventions alone, or when the patient expresses a preference for pharmacological treatment. They are less likely to be sufficient when depression is embedded in ongoing trauma, chronic stress, untreated sleep disorders, or high levels of systemic inflammation. In such cases, multimodal treatment is not optional—it is necessary.

Third, monitor for heterogeneity of response. Not all patients respond to SSRIs, and not all who respond do so fully. Genetic testing for serotonin transporter polymorphisms remains of uncertain clinical utility, but attention to early-life adversity, current inflammation markers (such as C-reactive protein), and comorbid conditions (particularly metabolic syndrome) may help predict response and guide treatment selection.

Fourth, integrate serotonin-modulating interventions beyond pharmacology. Regular aerobic exercise has been shown in meta-analyses to increase serotonin turnover and reduce depressive symptoms with effect sizes comparable to SSRIs (Schuch et al., 2023, *British Journal of Sports Medicine*). Bright light exposure, particularly in the morning, influences serotonin synthesis and circadian alignment. Dietary tryptophan availability, omega-3 fatty acids, and gut microbiome health all modulate serotonergic signaling and warrant clinical attention.

Finally, use the language of prediction and revision. Help patients understand that their mood is not a direct readout of serotonin levels but an output of a nervous system that has learned to predict certain outcomes based on past data. SSRIs and other interventions can support the system's capacity to update those predictions, but the patient remains the agent of revision. This framing preserves agency, reduces passivity, and aligns treatment with the reality of how change occurs.

If you are considering or currently using an SSRI, understand that the medication is not replacing a missing chemical. It is modulating the conditions under which your nervous system can revise its predictions. That revision requires your participation.

Start by noticing what your nervous system is predicting. When you wake in the morning and feel the familiar weight, ask: what is my system expecting today? Often the answer is threat, futility, or invisibility. These are not irrational predictions—they are based on data your system has collected. But they are revisable.

Pair any serotonin-modulating intervention—whether medication, exercise, or light exposure—with behavioral experiments that provide disconfirming evidence. If your system predicts that reaching out will result in rejection, reach out anyway, in small doses, and notice what actually happens. If it predicts that effort will not be rewarded, choose one small effort and track the outcome. The goal is not to "think positive" but to generate data.

Regulate your sleep with the same seriousness you would regulate medication. Serotonin synthesis is tightly coupled to circadian rhythms, and chronic sleep disruption undermines serotonergic signaling regardless of pharmacological intervention. Aim for consistent sleep and wake times, morning light exposure, and reduction of blue light in the evening.

Consider movement. Aerobic exercise increases serotonin turnover, enhances neuroplasticity, and provides immediate feedback that effort produces outcome—a prediction many depressed nervous systems have learned to doubt. You do not need to love exercise. You need only to move regularly enough that your system begins to update its model.

If you are working with a clinician, ask questions. What is the expected timeline for response? What should I do if I do not respond? What non-pharmacological interventions are we integrating? How will we know if this is working? These are not challenges to authority—they are collaborations in revision.

Finally, validate the intelligence of your system. It is not broken. It has learned to predict a world that may no longer exist, or that exists only partially. The work is not to override it but to offer it new information, consistently and compassionately, until the prediction shifts.